[{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Drug Farm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"DF-006","moa":"ALPK1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Aligos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"ALG-000184","moa":"||Capsid assembly","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"First Affiliated Hospital of Zhejiang University","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"YPEG-rhEPO","moa":"Erythropoietin receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ First Affiliated Hospital of Zhejiang University","highestDevelopmentStatusID":"8","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ First Affiliated Hospital of Zhejiang University"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Peking University Third Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Telpegfilgrastim","moa":"G-CSF receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University Third Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University Third Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Peking University Third Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Telpegfilgrastim","moa":"G-CSF receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University Third Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University Third Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"YPEG-rhG-CSF","moa":"G-CSF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"YPEG-rhG-CSF","moa":"G-CSF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Filgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Peking Union Medical College Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Peking Union Medical College Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Peking Union Medical College Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Tongji Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Inpegsomatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Tongji Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Tongji Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Tongji Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Pegylated Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Tongji Hospital","highestDevelopmentStatusID":"9","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Tongji Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Tongji Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"YPEG-rhGH","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Tongji Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Tongji Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Peginterferon Alfa","moa":"Interferon alpha\/beta receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Xiamen Amoytop Biotech Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Peginterferon Alfa-2a","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Xiamen Amoytop Biotech Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Xiamen Amoytop Biotech Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Peking University First Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University First Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University First Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Peking University First Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University First Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University First Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Peking University First Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University First Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University First Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Peking University First Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University First Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University First Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Peking University First Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University First Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University First Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Peking University People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University People's Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University People's Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Zhongnan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ACT500","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Zhongnan Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Zhongnan Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Pegylated rhEPO","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Shanghai Jiaotong University Affiliated First People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Recombinant Human GM-CSF","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Shanghai Jiaotong University Affiliated First People's Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Shanghai Jiaotong University Affiliated First People's Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Xiamen Amoytop Biotech Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Recombinant Human Interleukin-11","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase IV","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Aligos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0.11,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd","highestDevelopmentStatusID":"2","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd"}]
Find Clinical Drug Pipeline Developments & Deals by Xiamen Amoytop Biotech Co., Ltd
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
